22:40 25-10-2014
MAIN Russian
About us On-line subscription
KazakhstanTajikistanUzbekistanKyrgyzstanTurkmenistanWorld
POLITICSBUSINESSINCIDENTSSOCIETYCULTURESPORTANALYSISSCIENCE
British executive accused in China drug bribery

Bishkek (AKIpress) - china-accuses-glaxosmithkline-of-enormous-and-elaborate-bribery-network Chinese police on Wednesday accused a British executive of GlaxoSmithKline of leading a sprawling scheme to bribe doctors and hospitals to use its drugs.

The announcement was the first time a foreign employee in China of British-based GSK was accused in the investigation announced last July. It highlighted the widespread use of payments to doctors and hospitals by sellers of drugs and medical equipment in a poorly funded health system that Chinese leaders have promised to improve, the AP reported.

The executive, Mark Reilly, is accused of operating a "massive bribery network," said a police official, Gao Feng, at a news conference. He said the case had been handed over to prosecutors for formal indictment, the AP said. 

Beginning in January 2009, Reilly is accused of ordering his sales team to pay doctors, hospital officials and health institutions to use GSK's products, said Gao, deputy director of the Ministry of Public Security's economic crimes unit. He said that resulted in "illegal revenue" of billions of yuan (hundreds of millions of dollars).

"GSK's bribery activities ran through its entire operations in China," Gao said.

Gao said Reilly is in China but gave no other details of his status. He said dozens of other people also were implicated but gave no names or other details.

The British Embassy in Beijing said diplomats were in regular contact with Reilly and were providing "consular assistance." The embassy declined to comment further while the case was under way.

Reilly was GSK's senior vice president of pharmaceuticals for China and Hong Kong and former general manager for China.

"We take the allegations that have been raised very seriously. They are deeply concerning to us and contrary to the values of GSK," the company said in a statement. "We want to reach a resolution that will enable the company to continue to make an important contribution to the health and welfare of China and its citizens."

Police previously identified four Chinese employees of GSK who they said confessed to bribery.

A second foreign drugmaker, AstraZeneca, said in July that police in Shanghai were investigating one of its salespeople. The company has given no information since then.

Chinese state media have publicized the bribery investigations of GSK and AstraZeneca. But economists who study Chinese health care say such payments are more widely used by China's domestic drug manufacturers.

Doctors and hospitals routinely accept informal payments from patients and suppliers of medical goods to top up low salaries and cover gaps in budgets.

Hospitals also raise money by adding surcharges to drug prices and assigning employees sales quotas. That can also distort treatment by encouraging overuse of expensive drugs or procedures.

Gao said Reilly used bribery to meet sales targets set by GSK's head office.

The company charged prices up to seven times the level charged in other countries, Gao said. He said that before a patent on one of its drugs was due to expire in 2012, GSK paid bribes to discourage hospitals from switching to cheaper generic versions.

"The more it bribed, the more drugs it could sell," he said.

GSK employees obstructed previous inquiries by bribing investigators and other government officials, Gao said.

In a separate statement, police in the central city of Changsha, where the investigation began, said Reilly and two Chinese executives also are accused of bribing government officials in Beijing and Shanghai.


Twitterfacebookprint
15:44 14.05.2014
LATEST NEWS
15:54 Vice PM Dil, President of Turkmenistan discuss Atambayev's visit to Ashgabat15:48 Kyrgyzstan needs to procure 2.2 million tons of coal for autumn-winter period15:34 Tenge/som exchange rate rises by 8.93% since February tenge devaluation in Kazakhstan - National Bank15:07 Vietnam business tycoon Ha Van Tham arrested for 'fraud'15:03 Kyrgyzstan and Tajikistan conduct drills on elimination of consequences from emergency situations14:52 Nazarbayev to take part in 10th World Islamic Economic Forum in Dubai14:36 Talas unveils sculpture of writer Chingiz Aitmatov14:30 Atambayev congratulates employees of local governments on their professional day14:08 Chinese Vice FM attends reception marking 23rd anniversary of Independence of Tajikistan13:44 New York axe attack 'terrorist act by Muslim convert'13:21 Gazprom to supply 330 mln m3 of gas to Jambul TPP to reduce cost of electricity supply from Kazakhstan13:19 90 projects to be approved within Business Roadmap 2020 in Kazakhstan's Karaganda12:27 Rusnano representatives discuss issues of nanotechnology in Kyrgyzstan12:21 86.7% of grain produced in Kazakhstan so far - Ministry12:03 Egypt imposes state of emergency in Sinai after attacks11:15 Kyrgyzstan has become attractive for investors after reforms for favorable conditions for business - Deputy Economy Minister10:53 Kyrgyzstan signs a number of investment deals for doing business better10:21 Google's Alan Eustace beats Baumgartner's skydiving record10:18 Kazakh oil output to rise with Kashagan after 2020 - official09:59 Ebola outbreak: Cases pass 10,000, WHO reports
Astana
-4° C
Ashgabat
+23° C
Bishkek
+19° C
Dushanbe
+19° C
Tashkent
+22° C
exchange rates
 
71.18
56.25
9.20
1.35
228.80
180.87
29.57
4.32
6.33
4.99
0.82
0.12
3084.28
2367.40
385.74
61.13
3.60
2.85
0.47
0.07

© AKIpress News Agency - 2001-2014
Use of the AKIpress.com materials must be accompanied by a hyperlink to www.akipress.com
Our address:
Moskovskaya str. 189, Bishkek, the Kyrgyz Republic
e-mail: english@akipress.org, akipressenglish@gmail.com;
Tel/Fax: +996(312)90-07-75